Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design

Ryan Cross

Senior Science Correspondent

Nabla Bio, a small startup founded by scientists from geneticist George Church’s lab at Harvard Medical School, has formed drug discovery collaborations with AstraZeneca, Bristol …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Takeda to lay off more employees in Massachusetts

Corrected: Boehringer Ingelheim, Gubra put a second candidate into the obesity race

Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech

Eisai takes over development of ADC after Bristol Myers ends $650M collaboration

FTC investigates Teva over patents, doubling down on 'bogus' Orange Book listings

Cassava says two senior employees included in federal probes

Ex­clu­sive: Har­vard start­up rais­es $26M, strikes three phar­ma part­ner­ships for AI an­ti­body de­sign

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Cor­rect­ed: Boehringer In­gel­heim, Gubra put a sec­ond can­di­date in­to the obe­si­ty race

Lil­ly inks ra­dio­phar­ma deal with Ra­dio­net­ics, with rights to buy the biotech

Ei­sai takes over de­vel­op­ment of ADC af­ter Bris­tol My­ers ends $650M col­lab­o­ra­tion

FTC in­ves­ti­gates Te­va over patents, dou­bling down on 'bo­gus' Or­ange Book list­ings

Cas­sa­va says two se­nior em­ploy­ees in­clud­ed in fed­er­al probes

Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design

Takeda to lay off more employees in Massachusetts

Corrected: Boehringer Ingelheim, Gubra put a second candidate into the obesity race

Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech

Eisai takes over development of ADC after Bristol Myers ends $650M collaboration

FTC investigates Teva over patents, doubling down on 'bogus' Orange Book listings

Cassava says two senior employees included in federal probes